References
- Kyaw MH, Rose CE Jr, Fry AM, et al. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis. 2005;192:377–386.
- Klemets P, Lyytikäinen O, Ruutu P, et al. Invasive pneumococcal infections among persons with and without underlying medical conditions: implications for prevention strategies. BMC Infect Dis. 2008;8:96.
- Sinisalo M, Aittoniemi J, Oivanen P, et al. Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia. Br J Haematol. 2001;114:107–110.
- Sinisalo M, Vilpo J, Itälä M, et al. Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia. Vaccine. 2007;26:82–87.
- Hinge M, Ingels HA, Slotved HC, Mølle I. Serologic response to a 23-valent pneumococcal vaccine administered prior to autologous stem cell transplantation in patients with multiple myeloma. APMIS. 2012;120:935–940.
- Cordonnier C, Labopin M, Chesnel V, et al. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. Clin Infect Dis. 2009;48:1392–1401.
- Rodgers GL, Klugman KP. The future of pneumococcal disease prevention. Vaccine. 2011;29(Suppl 3):S43–S48.
- Skinner JM, Indrawati L, Cannon J, et al. Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model. Vaccine. 2011;29:8870–8876.
- Pulido M, Sorvillo F. Declining invasive pneumococcal disease mortality in the United States, 1990-2005. Vaccine. 2010;28:889–892.
- Jokinen J, Rinta-Kokko H, Siira L, et al. Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children - a population-based study. PLoS One. 2015;10:e0120290.
- Klemets P, Lyytikäinen O, Ruutu P, et al. Trends and geographical variation in invasive pneumococcal infections in Finland. Scand J Infect Dis. 2008;40:621–628.
- Brenner H, Hakulinen T. Reduction in selective under-ascertainment bias in population-based estimates of cancer patient survival by age adjustment. Eur J Cancer. 2005;41:1788–1793.
- Wong A, Marrie TJ, Garg S, et al. SPAT Group. Increased risk of invasive pneumococcal disease in haematological and solid-organ malignancies. Epidemiol Infect. 2010;138:1804–1810.
- Engelhard D, Cordonnier C, Shaw PJ, et al. Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. Br J Haematol. 2002;117:444–450.
- Luján M, Burgos J, Gallego M, et al. Effects of immunocompromise and comorbidities on pneumococcal serotypes causing invasive respiratory infection in adults: implication for vaccine strategies. Clin Infect Dis. 2013;57:1722–1730.
- Debbache K, Varon E, Hicheri Y, et al. The epidemiology of invasive Streptococcus pneumoniae infections in onco-haematology and haematopoietic stem cell transplant patients in France. Are the serotypes covered by the available anti-pneumococcal vaccines? Clin Microbiol Infect. 2009;15:865–868.
- Cohen AL, Harrison LH, Farley MM, et al. Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization. AIDS. 2010;2253–2262.
- Ruutu P, Kuusi M, Nuorti PJ, Koskinen, S. Communicable diseases. In: Aromaa A, Koskinen S, editors. Health and functional capacity in Finland: baseline results of the Health 2000 examination survey. Helsinki: National Public Health Institute, 2004. pp 67–69.
- Olaya-Abril A, Jiménez-Munguía I, Gómez-Gascón L, et al. Identification of potential new protein vaccine candidates through pan-surfomic analysis of pneumococcal clinical isolates from adults. PLoS One. 2013;8:e70365.